

## Statement From BIOTECanada Regarding PMPRB Implementation Delay

**June 29, 2021 [OTTAWA]** BIOTECanada is supportive of the implementation delay of the changes to the PMPRB announced today by the Government of Canada. The industry recommends using the implementation delay to work with the government towards providing a more holistic policy approach for the sector which recognizes the interconnectivity of the ecosystem which includes early-stage biotech companies and large multinational pharmaceutical companies. Moreover, a more competitive policy approach for the sector will greatly enhance the significant investments governments have already directed into the sector over the past twelve months.

Recognizing the importance of the sector in delivering solutions for the current pandemic, preparing for future pandemics and supporting the post-pandemic economic rebuild, the government's recent budget provided significant new program commitments and investments aimed at building a robust and globally competitive Canadian biotech sector and biomanufacturing capacity. These commitments are greatly welcomed by the industry as they will make Canada more competitive in attracting investment, commercializing science, and creating the highly skilled jobs of today and tomorrow. Another important legacy of the Canadian government's pandemic response has been the constructive working relationship the government has established with the industry to identify key Canadian assets and areas for investment. The recent Sanofi and Resilience Biotechnologies investment-partnership deals will be significant strategic assets for Canada going forward. Canada now has an opportunity to build on the constructive relationship established during the pandemic to leverage the government's significant investments and successfully meet its preparedness and economic rebuild objectives.

The industry looks forward to collaborating with the government, building on recent investments to develop a more sustainable path forward supporting access to emerging technologies, an affordable healthcare system and the growth of Canada's biotech ecosystem more broadly.

### About BIOTECanada

BIOTECanada is the national association for Canada's biotech industry. The Association's over 240 member companies represent the diverse Canadian biotech industry ecosystem which extends across the country with unique hubs in every province. BIOTECanada's membership reflects the Canadian biotech ecosystem, which is a mix of large multinational pharmaceutical companies, early-stage biotech companies of varying sizes, drug discovery and accelerator organizations, research centers, universities, and investors.